EPI和THP预防浅表性膀胱癌术后复发的疗效及对患者生存质量的影响  

Comparison of EPI and THP in the Prevention of Postoperative Recurrence of Superficial Bladder Cancer and Its Impact on Quality of Life

作　　者：陈帅 盛易明[1] 彭国林[1] 邓兰[1] 吴文清 周美秀[1] CHEN Shuai;SHENG Yiming;PENG Guolin(No. 184 Hospital of the People＇s Liberation Army, Yingtan, 335000)

机构地区：[1]解放军第一八四医院,335000

出　　处：《实用癌症杂志》2018年第6期1005-1007,1027,共4页The Practical Journal of Cancer

摘　　要：目的探讨应用EPI和THP预防浅表性膀胱癌术后复发的疗效及对患者生存质量的影响。方法选取行浅表性膀胱癌术的110例SBC患者展开临床分析,随机分成研究组(THP)与对照组(EPI)。研究组使用吡柔比星实施术后膀胱内灌注治疗,对照组使用表柔比星实施术后膀胱内灌注治疗。对2组患者均随访12月,通过观察2组患者经治疗后的复发率来判断2种药物的疗效,并对比2组的不良反应、生活质量。结果研究组经治疗后复发率为10.9%,对照组经治疗后复发率为16.4%(P>0.05);研究组经治疗后不良反应发生率为54.5%,对照组经治疗后不良反应发生率为47.3%(P>0.05);2组生活质量评分无统计学差异。结论 EPI和THP的药理作用相似,均可以有效地预防行浅表性膀胱癌术后复发的结局,且不良反应发生率也相当,均具有临床推广的价值。Objective To investigate the efficacy of EPI and THP in the prevention of postoperative recurrence of superficial bladder cancer and its influence on the quality of life of patients with superficial bladder cancer. Methods 110 patients with superficial bladder cancer who had been treated with SBC surgery were randomly divided into the study group（ THP） and the control group（ EPI）. The study group treated with intravesical instillation of pirarubicin. The control group treated with epirubicin after intravesical instillation. 2 groups of patients were followed up for 12 months. The efficacy of the 2 drugs was evaluated by observing the recurrence rate of the 2 groups after treatment,and the adverse reactions and quality of life in the 2 groups were compared. Results The study group after treatment,the recurrence rate was 10. 9%,the control group after treatment,the recurrence rate was 16. 4%（ P 〉 0. 05）; the study group after treatment,the incidence of adverse reaction was 54. 5%,the control group after treatment,the incidence of adverse reaction was 47. 3%（ P 〉 0. 05）; quality of life of the 2 groups had no statistical difference. Conclusion The pharmacological effects of EPI and THP are similar,which can effectively prevent the recurrence of superficial bladder cancer after operation,and the incidence of adverse reactions is the same. It is worthy of clinical promotion.

关 键 词：表柔比星 吡柔比星 浅表性膀胱癌 疗效 复发 

分 类 号：R737.14[医药卫生—肿瘤]